+++ title = "Synthetic genomics" slug = "synthetic-genomics" description = "Synthetic genomics is the branch of life engineering concerned with the design, chemical synthesis, and assembly of complete genomes or large portions of genomes — the construction of an organism's entire hereditary material from designed sequence rather than from modification of existing biological templates. The field is the most ambitious wing of contemporary life engineering, operating at the scale of complete cellular life rather than at the sub-system scale of synthetic biology or the modify-existing scale of genetic engineering. On the Wheel of Heaven framework, synthetic genomics is the sub-discipline whose specific scale of operation — whole-organism construction from designed sequence — most directly matches the operational scale at which the Raëlian source material describes the Elohim's work." template = "wiki-page.html" toc = true [extra] category = "Science & Technology" editorial_pass = "2026-05" entry_type = "discipline" claim_type = "direct" alternative_names = ["Whole-genome synthesis", "Genome engineering", "Genome-scale design"] [extra.infobox] type = "Engineering sub-discipline of life engineering concerned with whole-genome design and synthesis" parent_field = "Life engineering" sister_fields = "Genetic engineering; synthetic biology; xenobiology" distinguishing_feature = "Operates at the scale of complete genomes rather than at the sub-system or single-gene scale" foundational_milestones = "Chemical synthesis of phage φX174 genome (Smith, Hutchison, and Venter, 2003); synthesis of *Mycoplasma genitalium* genome (Gibson and colleagues, 2008); JCVI-syn1.0 — first cell with entirely synthetic genome (Gibson and colleagues, 2010); JCVI-syn3.0 — first minimal synthetic cell, 473 genes (Hutchison and colleagues, 2016); JCVI-syn3A — stabilised minimal-cell platform (Pelletier and colleagues, 2021); Sc2.0 — synthetic *Saccharomyces cerevisiae* genome (international consortium, 2011–present)" key_techniques = "Hierarchical assembly of synthetic oligonucleotides; genome transplantation; yeast as DNA-assembly host; whole-chromosome synthesis" current_status = "Active scientific discipline; complete bacterial genomes now routinely synthesised; eukaryotic-genome work ongoing; multicellular-genome synthesis not yet achieved" framework_significance = "The sub-discipline whose operational scale — whole-organism construction from designed sequence — most directly matches the scale of the Elohim's work as described in the source material" +++ **Synthetic genomics** is the branch of [life engineering](../life-engineering/) concerned with the design, chemical synthesis, and assembly of complete genomes or large portions of genomes — the construction of an organism's entire hereditary material from designed sequence rather than from the modification of existing biological templates. It is the most ambitious wing of contemporary life engineering and the one whose scale of operation most directly approaches the scale at which the Raëlian source material describes the work of the Elohim civilisation. Where [synthetic biology](../synthetic-biology/) more broadly operates at the level of sub-systems and components, and where [genetic engineering](../genetic-engineering/) operates at the level of modifications to existing genomes, synthetic genomics operates at the level of the genome itself. The field's central achievement to date is the production of free-living cellular organisms whose every base of DNA has been chemically synthesised in the laboratory: a *Mycoplasma mycoides* strain whose 1.08-megabase genome was synthesised and assembled by Daniel Gibson and colleagues at the J. Craig Venter Institute and published in 2010 (the strain JCVI-syn1.0), and a subsequent minimal-cell line whose genome was iteratively reduced to 473 genes — the smallest known genome of any free-living organism (JCVI-syn3.0, 2016, and the stabilised derivative JCVI-syn3A, 2021). The field's most ambitious ongoing project is the international Synthetic Yeast 2.0 consortium, which has been working since 2011 on the synthesis of a complete redesigned genome for the yeast *Saccharomyces cerevisiae* — the first eukaryotic genome to be constructed entirely from designed sequence. The field's name was coined and substantially shaped by the J. Craig Venter Institute and the affiliated company Synthetic Genomics, Inc., founded by Venter in 2005. The institutional concentration of the early synthetic-genomics work in one research group is a distinctive feature of the field: where synthetic biology has been from the beginning a distributed international effort, synthetic genomics has been substantially driven by the JCVI and its collaborators, with the Sc2.0 consortium representing the broadest geographic distribution the field has yet seen. The reading on which the framework's interest in synthetic genomics depends is not contested. The scientific reality of the field — its techniques, its achievements, its commercial and clinical deployments — is established and documented across a substantial scientific literature. What is contested is the framework's interpretation of the field's significance: the claim that the contemporary terrestrial development of whole-genome synthesis is the present-day local instance of a capability the source material attributes to the Elohim civilisation. The corpus presents the field accurately as it currently stands, registers the framework's reading of its significance in a clearly demarcated section, and refers the broader convergence argument to the [life engineering](../life-engineering/) entry where it is developed at full length. ## Definition and scope The boundaries of synthetic genomics as a sub-discipline are reasonably well-defined in practice, though the field has been variously positioned by different authors and institutional actors over the past two decades. A brief survey of the principal usages clarifies what the entry means by the term. ### The narrow definition The narrowest definition treats synthetic genomics as the construction of complete genomes from chemically synthesised DNA — the laboratory production of an entire genome (typically of a bacterium or yeast) from designed sequence, followed by its transplantation into a recipient cell or its assembly within a host. On this definition, the field is distinguished from synthetic biology by scale and from genetic engineering by mode of construction: where synthetic biology builds sub-systems and genetic engineering modifies existing genomes, synthetic genomics builds whole genomes from designed sequence. ### The broader definition A broader definition extends the term to include large-segment genome construction (the synthesis of complete chromosomes or other large genome regions) and the systematic redesign of genomes for specified purposes (the codon-recoding work of the Church and Isaacs groups, in which specific codons are removed from a genome and reassigned). On this definition, the field includes both complete-genome synthesis and the major sub-genome interventions that the same techniques permit. ### The aspirational definition A still broader definition, more common in commentary than in laboratory practice, treats synthetic genomics as the engineering discipline whose ultimate scope is the *design from first principles* of complete organisms — moving beyond the synthesis of redesigned versions of existing genomes to the design of wholly novel genomes for organisms with no antecedent in the natural biosphere. The aspirational definition has not been realised in practice; the synthetic-genomics work to date has synthesised *redesigned* versions of *existing* genomes rather than wholly novel ones. The aspirational definition nonetheless captures the field's longer-term ambition and is the definition most directly relevant to the framework's reading. ### The usage adopted in this entry The entry adopts the narrow definition as primary — synthetic genomics as the construction of complete genomes from chemically synthesised DNA — with the broader and aspirational definitions recognised as relevant complementary scopes. The framework's interest extends across all three; the discussion below treats each at the relevant points. ## Historical development The history of synthetic genomics is shorter than the history of synthetic biology more broadly, since the technical capability for whole-genome synthesis emerged only in the 2000s. The pre-history reaches back to earlier work on long-DNA synthesis and viral-genome assembly; the modern field dates from the 2000s and is substantially concentrated in the J. Craig Venter Institute and the Sc2.0 consortium. ### Pre-history: viral-genome synthesis and the read–write gap Before the synthesis of cellular genomes became feasible, the question of whether the techniques of chemical DNA synthesis could be scaled to genome-scale assemblies was addressed through the synthesis of viral genomes, which are substantially smaller than bacterial genomes (typically thousands rather than millions of base pairs) and therefore within reach of earlier synthesis methods. The foundational work on viral-genome synthesis was the **2002 chemical synthesis of poliovirus** by Eckard Wimmer and colleagues at SUNY Stony Brook, which assembled the complete 7.5-kilobase poliovirus genome from mail-ordered DNA fragments and demonstrated that the resulting RNA generated infectious viral particles in mammalian cell culture. The Wimmer work is more commonly cited as the foundational synthetic-biology demonstration of the era (and is treated in the synthetic-biology entry under that heading), but it is also the immediate precursor of the synthetic-genomics programme: the first demonstration that a complete genome could be assembled from chemically synthesised oligonucleotides and made functional. A foundational synthetic-genomics achievement followed in **2003** with the chemical synthesis of the bacteriophage **φX174** genome by Hamilton Smith, Clyde Hutchison, and J. Craig Venter at the (then newly established) Institute for Biological Energy Alternatives — the precursor organisation to the JCVI. The φX174 work assembled the 5.4-kilobase phage genome in approximately two weeks, demonstrating that the technical bottlenecks of the early 2000s could be overcome with careful methodology and establishing the technical foundation for the larger-scale synthesis projects that would follow. The broader context of these foundational works was the recognition, in the post-Human Genome Project period of the early 2000s, that the *read* and *write* sides of DNA technology had developed unevenly. Genome sequencing — the read side — had matured rapidly across the 1990s, culminating in the completion of the Human Genome Project in 2003. Genome synthesis — the write side — had lagged substantially behind. The closing of the read–write gap became one of the explicit programmatic goals of synthetic genomics, with the *cost-per-base* of synthesis falling steadily across the past two decades and the *scale* of feasible synthesis increasing correspondingly. ### 2005–2010: the establishment of the field The years from 2005 through 2010 saw the formalisation of synthetic genomics as a named discipline, the founding of the relevant institutional structures, and the first complete bacterial-genome synthesis. **Synthetic Genomics, Inc.** was founded by J. Craig Venter and Hamilton Smith in 2005, as the commercial counterpart to the J. Craig Venter Institute's research programme. The company's establishment named the field. Across the subsequent decade Synthetic Genomics pursued both research applications (in collaboration with the JCVI) and commercial applications, including substantial investment in algal biofuels (in partnership with ExxonMobil) and engineered microbes for various industrial applications. The **2008 publication** by Daniel Gibson, Hutchison, Smith, Venter, and colleagues of the complete chemical synthesis and assembly of the *Mycoplasma genitalium* genome was the field's first complete-bacterial-genome milestone. The 583-kilobase genome — one of the smallest known bacterial genomes — was assembled hierarchically: short oligonucleotides were combined into intermediate fragments through PCR and overlap extension, the intermediate fragments were combined into larger assemblies through recombination in *E. coli*, and the final assembly of the complete genome was performed by recombination in yeast. The work demonstrated that complete bacterial genomes could be synthesised from chemical reagents and reassembled as functional circular DNA molecules. The 2008 work also established the *yeast as DNA-assembly host* methodology that would become central to subsequent synthetic-genomics work. *Saccharomyces cerevisiae* has unusually efficient homologous-recombination machinery and can assemble large DNA molecules from many overlapping fragments through recombination — a property that no other commonly used laboratory organism shares to the same degree. The use of yeast as a DNA-assembly host has been one of the field's distinctive technical contributions and is now standard methodology for large-scale DNA assembly across the broader life-engineering enterprise. ### 2010: JCVI-syn1.0 The **2010 publication** of **JCVI-syn1.0** by Daniel Gibson and colleagues was the field's first complete-cellular-organism achievement and remains, by general consensus, the most significant single demonstration in the history of synthetic genomics. The project synthesised the 1.08-megabase *Mycoplasma mycoides* genome from approximately one thousand short oligonucleotides supplied by commercial DNA-synthesis vendors, assembled the oligonucleotides through hierarchical recombination in *E. coli* and yeast, and transplanted the completed synthetic genome into a *Mycoplasma capricolum* recipient cell from which the native genome had been removed. The recipient cell, now controlled by the synthetic genome, began to express the proteins encoded by the synthetic *Mycoplasma mycoides* sequence; daughter cells inherited the synthetic genome; the resulting population was a free-living bacterium whose every base of DNA had been chemically synthesised in the laboratory. The organism was named JCVI-syn1.0 and the publication, in *Science*, identified the work as "creation of a bacterial cell controlled by a chemically synthesized genome." The synthetic genome contained four *watermarks* — encoded text written into non-coding regions of the chromosome, serving both as proof that the genome was the synthetic version (rather than a wild-type contaminant) and as the project team's symbolic statement of what the work represented. The watermarks encoded the names of the forty-six project contributors, the URL of the project, an HTML interpreter, and three literary quotations: James Joyce's "To live, to err, to fall, to triumph, to recreate life out of life," Robert Oppenheimer's "See things not as they are, but as they might be" (from American Prometheus, the Oppenheimer biography), and Richard Feynman's "What I cannot build, I cannot understand." The Feynman quotation is the field's effective motto. The constructive epistemology — that genuine understanding requires the ability to build — is the methodological commitment that distinguishes synthetic genomics from pre-constructive biology. The JCVI-syn1.0 work was the first demonstration that this commitment could be honoured at the scale of a complete free-living organism. ### 2016: JCVI-syn3.0 and the minimal cell The **2016 publication** of **JCVI-syn3.0** by Clyde Hutchison, Gibson, Venter, and colleagues was the second major JCVI achievement and produced what remains the smallest known genome of any free-living organism. The project's design proceeded by iterative reduction rather than direct minimal-genome design. Starting from the JCVI-syn1.0 platform, genes were progressively removed and the resulting organisms tested for viability. Non-essential genes — those whose deletion left the organism still capable of survival in laboratory growth media — were removed; essential genes were retained. The process continued until the genome could not be further reduced without producing non-viable cells. The resulting organism, JCVI-syn3.0, has a genome of 531 kilobases encoding 473 genes — less than half the size of the syn1.0 genome from which it was derived. The 473 genes of JCVI-syn3.0 constitute a working minimal gene set for cellular life under laboratory conditions: the irreducible core of what is required for an organism to grow, reproduce, and maintain itself in rich growth media. Approximately 30 percent of the 473 essential genes had functions that were uncharacterised at the time of publication — an indication of how much remains to be learned about the molecular basis of even minimal cellular life. The JCVI-syn3.0 work established several points that have shaped the subsequent field. First, the minimal genome is substantial: 473 genes, encompassing approximately 530 kilobases, are required for free-living cellular life — far more than the most aggressive theoretical estimates had projected. Second, a substantial fraction of the essential genome remains functionally uncharacterised, even after intensive study. Third, the iterative-reduction methodology is feasible — the design of a minimal genome through systematic deletion of non-essential genes is a workable engineering approach to the minimal-cell problem. ### 2021: JCVI-syn3A and the stable platform The **2021 publication** of **JCVI-syn3A** by Pelletier and colleagues addressed a practical limitation of the syn3.0 platform: the syn3.0 cells, while viable, exhibited pleomorphic (irregular) cellular forms and abnormal cell division behaviour that made them difficult to work with in standard laboratory conditions. The JCVI team identified a partially minimised intermediate produced during the syn3.0 construction — a strain with 19 additional genes beyond syn3.0 — that retained normal cell division behaviour and stable cell morphology. The 19-additional-gene strain was named JCVI-syn3A. The syn3A platform combines most of the genome reduction of syn3.0 with the practical workability of the syn1.0 cellular phenotype, and has become the working chassis for the broader synthetic-minimal-cell research community. As of the mid-2020s, **JCVI-syn3A** is in use at more than forty laboratories worldwide as a platform for investigating the molecular basis of cellular life and for constructing further synthetic-biological systems. The syn3A platform's significance is not in the genome reduction itself (syn3.0 reduced the genome further) but in the practical workability it provides as a chassis for further work. A further derivative, **JCVI-syn3B**, has been used in studies of host-microbe interaction — particularly the interaction of minimised bacterial cells with mammalian cells in coculture, with implications for both basic research and possible therapeutic applications. ### The Sc2.0 consortium and eukaryotic-genome synthesis The **Synthetic Yeast 2.0 (Sc2.0)** project, initiated in 2011 by Jef Boeke at Johns Hopkins University and now distributed across an international consortium of laboratories, is the most ambitious ongoing project in synthetic genomics and the first major effort to extend whole-genome synthesis to a eukaryotic organism. The project's goal is the synthesis of a complete redesigned genome for *Saccharomyces cerevisiae* — the yeast used in baking, brewing, and laboratory research, and the first eukaryotic organism whose complete genome was sequenced (1996). The Sc2.0 genome is not a wholesale redesign but a systematic modification of the natural yeast genome: introns, transposable elements, and some redundant tRNA genes are removed; recoded codons are introduced to create unused codons that can later be reassigned to encode unnatural amino acids; and SCRaMbLE (Synthetic Chromosome Rearrangement and Modification by LoxP-mediated Evolution) sites are introduced throughout the genome to enable programmed genome rearrangement under laboratory induction. The project has been organised around the synthesis of individual chromosomes (sixteen in total) by participating laboratories worldwide. Individual chromosome syntheses were reported across the 2010s, with the first synthetic chromosome (synIII) published in 2014. The combination of all sixteen synthetic chromosomes into a single yeast strain — the complete synthetic yeast — has been the project's culminating goal across the past several years, with significant progress reported in 2023 and 2024. The Sc2.0 work is the field's first major eukaryotic-genome synthesis project and is substantially larger in scope than the JCVI bacterial-genome work. The *S. cerevisiae* genome is approximately 12 megabases — roughly twelve times the size of the JCVI-syn1.0 genome — and is divided into sixteen separate chromosomes that must each be synthesised, assembled, and integrated. The project has involved more than twenty laboratories worldwide and represents the most distributed effort in the field's history. ### Adjacent projects: codon recoding and genome refactoring Beyond the JCVI and Sc2.0 lines, several adjacent projects have applied synthetic-genomics methods to specific systematic interventions in existing genomes. The **GP-write project** (Genome Project-write), proposed in 2016 by Jef Boeke, George Church, and colleagues, has aimed to extend synthetic-genomics methods to larger and more complex genomes, including ultimately the human genome. The project has been controversial — the prospect of a synthetic human genome raises substantial ethical and societal concerns — and has proceeded on a slower timeline than originally proposed, with intermediate scientific goals (synthesis of smaller human genome regions, synthesis of viral and bacterial genomes adapted to particular research applications) as the primary near-term focus. The **codon-recoding work** of George Church, Farren Isaacs, and colleagues has produced the **rE.coli** strain (also called *Syn61* in some publications) — an *E. coli* strain in which seven specific codons have been replaced throughout the entire genome with synonymous alternatives, with the freed codons then available for reassignment to encode unnatural amino acids. The codon-recoding work is a form of large-scale genome refactoring that uses synthetic-genomics methods to make systematic changes across the entire genome rather than to construct a new genome from scratch. The **broader synthetic-chromosome work** in various laboratories — including the construction of synthetic plant chromosomes, mammalian artificial chromosomes for biotechnology applications, and various other large-DNA-construction projects — extends the field's methods into specific application areas. ## Intellectual foundations The intellectual foundations of synthetic genomics overlap substantially with those of synthetic biology more broadly (treated in the [synthetic biology](../synthetic-biology/) entry) but include several distinctive elements that bear specifically on whole-genome design. ### The constructive epistemology The constructive epistemology — that genuine understanding requires the ability to build — is the methodological commitment that distinguishes synthetic genomics from pre-constructive biology. The Feynman quotation encoded into the JCVI-syn1.0 watermarks is the field's effective motto: "What I cannot build, I cannot understand." The constructive epistemology motivates the field's most ambitious projects (the minimal cell, the synthetic yeast) by treating them as not only engineering achievements but also basic-science contributions. A minimal cell whose every gene is required for life is a working hypothesis about what is essential to cellular life; the construction of such a cell is simultaneously the validation of the hypothesis and the production of a working platform for further investigation. ### The minimal-genome programme The minimal-genome programme is the specific research programme that asks what is the smallest set of genes required for free-living cellular life. The question has been pursued by both top-down approaches (starting from a small natural genome like *Mycoplasma genitalium* and systematically removing genes) and bottom-up approaches (starting from theoretical predictions about which genes are essential and synthesising minimal genomes from designed sequence). The JCVI-syn3.0 work is the top-down minimal-genome programme's flagship achievement. The bottom-up approach has been pursued in parallel but has not produced an equivalent achievement; the gap between theoretical minimal-genome predictions and the empirically determined minimal genome remains substantial. ### Read–write asymmetry and its closing The historical asymmetry between DNA reading (sequencing) and DNA writing (synthesis) is one of the structural features of the field's development. Through the 1990s and early 2000s, the read side improved by orders of magnitude in cost and throughput while the write side improved more slowly. The cost-per-base of DNA synthesis has fallen across the past two decades to a level that makes megabase-scale assemblies economically feasible for research projects, but it remains higher than the cost-per-base of sequencing, and the gap defines what is currently feasible in synthetic genomics. The closing of the read–write gap is one of the field's standing programmatic concerns. ### Whole-genome design vs. modification The intellectual distinction between *whole-genome design from scratch* and *modification of existing genomes* is a constant theme in synthetic-genomics commentary. The JCVI work has been characterised by both proponents and critics as falling somewhere between the two: the syn1.0 genome was a chemically synthesised version of an existing biological genome (with some modifications), and the syn3.0 genome was iteratively reduced from syn1.0 rather than designed minimally from first principles. The genuinely de novo design of a complete genome — built from biochemical first principles rather than from the editing or reduction of existing biology — has not been achieved and remains one of the field's longer-term ambitions. ## Principal techniques The technical methodology of synthetic genomics combines several specific techniques that together permit the construction of large-scale designed DNA assemblies. ### Chemical oligonucleotide synthesis The foundational technical capability is the chemical synthesis of short DNA sequences (oligonucleotides) of defined sequence. The dominant chemistry is the *phosphoramidite method*, developed by Marvin Caruthers and colleagues in the late 1970s and early 1980s, which adds nucleotides to a growing DNA chain in a stepwise fashion under solid-phase synthesis conditions. The phosphoramidite method routinely produces oligonucleotides of up to approximately 200 bases in single-batch synthesis, with cost-per-base falling steadily across the past three decades. Beyond the 200-base scale, oligonucleotides must be assembled from shorter fragments through enzymatic methods. Contemporary commercial DNA synthesis supplies oligonucleotides at costs of approximately ten US cents per base for standard quality and substantially less for high-throughput applications. The cost-per-base has fallen by roughly half every two to three years across the past two decades, although the rate of improvement has slowed somewhat in recent years. ### Hierarchical assembly Whole-genome construction requires the assembly of synthesised oligonucleotides into progressively larger DNA molecules through a hierarchical series of joining steps. The dominant assembly methods include: **Gibson assembly** (developed by Daniel Gibson and colleagues at the JCVI in 2009) uses three enzymes acting in concert — an exonuclease that chews back the 5' ends of double-stranded DNA fragments, a polymerase that fills in single-stranded gaps, and a ligase that seals nicks — to join multiple DNA fragments with overlapping ends in a single isothermal reaction. Gibson assembly has become the dominant in vitro method for assembling DNA fragments up to approximately 100 kilobases, and is a workhorse technique across both synthetic genomics and synthetic biology more broadly. **Yeast homologous recombination** uses the unusually efficient homologous-recombination machinery of *Saccharomyces cerevisiae* to assemble DNA fragments inside yeast cells. The yeast-based assembly method permits the construction of substantially larger DNA molecules than in vitro methods — up to several megabases — and was the method used to assemble both JCVI-syn1.0 and the complete JCVI-syn3.0 genome. Yeast has become the de facto host for large-scale DNA assembly across the field. **Bacterial artificial chromosomes (BACs) and yeast artificial chromosomes (YACs)** are the long-DNA cloning vectors that permit the propagation and amplification of large DNA fragments in bacterial or yeast hosts. These vectors, developed in the late 1980s and 1990s, are the long-DNA infrastructure on which contemporary synthetic-genomics methods depend. ### Genome transplantation The transplantation of a complete synthetic genome into a recipient cell whose native genome has been removed is the technique that converts a chemically synthesised genome into a functional living organism. The technique was developed by the JCVI team in 2007 as part of the syn1.0 programme and remains the standard methodology for the production of cells controlled by synthetic genomes. The transplantation process involves isolating the synthetic genome from its assembly host (yeast, in the JCVI methodology), preparing recipient cells (Mycoplasma capricolum, in the JCVI methodology) under conditions that promote the uptake of foreign DNA, introducing the synthetic genome into the recipient cells, and selecting for cells that have lost their native genome and adopted the synthetic one. The process is technically challenging and remains substantially less reliable than the upstream synthesis and assembly steps; the gap between *being able to synthesise a genome* and *being able to make it functional in a cell* has been one of the field's structural challenges. ### Genome editing as a complement to synthesis The CRISPR–Cas systems and other genome-editing technologies provide a complementary capability that has substantially expanded what synthetic-genomics methods can achieve. The full historical treatment of CRISPR lives in the [life engineering](../life-engineering/) and [genetic engineering](../genetic-engineering/) entries; the specific relevance to synthetic genomics is that CRISPR permits targeted modification of synthetic genomes after their construction, expanding the range of interventions feasible without requiring a complete genome resynthesis. ## Applications The applications of synthetic genomics span basic research, biotechnology, and several emerging areas. The list below is partial and intended to convey the field's current operational scope rather than to be exhaustive. ### Basic research The principal application of synthetic genomics to date has been basic research: the use of synthetic minimal cells, redesigned eukaryotic genomes, and other engineered platforms as tools for understanding the molecular basis of cellular life. The JCVI-syn3A platform alone supports research at more than forty laboratories worldwide; the Sc2.0 platform supports a comparably large international research community. The specific research programmes enabled by synthetic-genomics platforms include: - **Minimal-cell biology** — Investigation of what is required for cellular life at the molecular level, using minimal cells as the experimental subject. - **Functional characterisation of the uncharacterised genome** — Systematic study of the approximately 30 percent of essential genes in syn3.0 whose function remained uncharacterised at publication, with the goal of producing complete functional accounts of cellular life. - **Construction of cellular models for specific processes** — Use of minimal cells as platforms for the study of cell division, membrane dynamics, metabolic regulation, and other fundamental cellular processes in a system whose every component is known. - **Tests of cellular-design principles** — The construction of cells with specific structural features (recoded codons, designed regulatory networks, designed metabolic pathways) tests whether those features can be successfully implemented and what consequences they have. ### Biotechnology The biotechnology applications of synthetic genomics overlap substantially with those of synthetic biology and genetic engineering more broadly. The specific contribution of synthetic-genomics methods is the construction of large-scale designed DNA assemblies — engineered metabolic pathways spanning many genes, designed genome regions for specific applications, and the eventual prospect of fully designed industrial organisms. The commercial deployments include engineered yeasts for various industrial applications (the Sc2.0 programme is partially motivated by the prospect of customisable industrial yeasts whose genome features can be programmed for specific products), engineered microbes for specific biosynthetic pathways, and various large-DNA biotechnology applications. ### Pharmaceutical applications The pharmaceutical applications of synthetic genomics include the construction of engineered viral vectors for gene therapy, the design of attenuated pathogens for vaccine development, and the construction of engineered cells for cell-based therapeutics. The mRNA-vaccine platforms deployed during the COVID-19 pandemic depend on synthetic-genomics methods for the construction of the relevant DNA templates from which the mRNA vaccines are transcribed. ### Speculative and future applications The longer-term applications of synthetic genomics include several speculative areas that are not currently within reach but represent the field's broader ambition. The construction of organisms engineered for survival under non-terrestrial conditions — high or low temperature, high radiation, non-standard atmospheric composition, low or absent water availability — is a research direction motivated by both astrobiology and the longer-term prospect of off-Earth settlement. Such organisms would need to be designed at the genome level to incorporate the specific protective and metabolic features required for survival under the relevant conditions. The capability does not yet exist at the level the application would require, but several research programmes are pursuing relevant aspects. The construction of multicellular organisms from designed genomes — the major remaining frontier of the field — would, if achieved, transform what synthetic genomics can do. The current state of the discipline operates almost entirely at the single-cell level; the transition to designed multicellular life is one of the field's standing aspirations. The construction of organisms with completely novel biochemistries — the integration of xenobiological components into whole-genome synthesis — is the convergence point between synthetic genomics and [xenobiology](../xenobiology/). Several xenobiology programmes have begun to construct genomes incorporating unnatural base pairs or recoded codons; the eventual prospect of complete genomes built on xenobiological substrates is a longer-term research aspiration. ## Limits and open questions The field's limits and unresolved questions are worth registering, both for accuracy and because they bound any broader interpretation of the field's achievements. - **The single-cell ceiling.** Contemporary synthetic genomics operates almost entirely at the level of single-cell organisms — bacteria and yeasts. The synthesis of a complete designed genome for a multicellular organism has not been achieved. The transition to multicellular synthesis would require not only larger-scale genome construction (animal and plant genomes are typically hundreds of megabases or larger) but also the design of the developmental programmes by which multicellular form emerges from individual cells — a problem that remains largely unsolved even for simpler model systems. - **The de novo design barrier.** All major synthetic-genomics achievements to date have synthesised *redesigned* versions of *existing* genomes rather than wholly novel ones. The JCVI-syn1.0 genome was a chemically synthesised version of the *Mycoplasma mycoides* genome with some modifications; the syn3.0 genome was iteratively reduced from syn1.0; the Sc2.0 genome is a systematic modification of the natural *S. cerevisiae* genome. The de novo design of a complete viable genome from biochemical first principles — the construction of a genome whose every feature has been designed rather than inherited from natural biology — has not been achieved. Whether this barrier is fundamental or merely a current technical limit is contested within the field. - **The function of the uncharacterised genome.** Approximately 30 percent of the essential genes in JCVI-syn3.0 had functions that were uncharacterised at publication. Subsequent work has reduced this fraction but a substantial gap remains. The synthesis of a complete genome whose every gene's function is fully understood — the engineering-discipline standard — has not been achieved even at the minimal-cell scale. - **Cost and throughput.** Despite the dramatic improvements in DNA synthesis cost across the past two decades, the cost-per-base of synthesis remains substantially higher than the cost-per-base of sequencing, and large-scale synthesis projects remain expensive. The closing of the read–write cost gap is a standing programmatic concern. - **Transplantation efficiency.** The transplantation of synthetic genomes into recipient cells — the step that converts chemical synthesis into a functional living organism — remains substantially less efficient than the upstream synthesis and assembly steps. The transplantation problem has been a continuing technical challenge across the field's history. - **Biosafety and dual use.** The synthesis of complete viral genomes (the 2002 poliovirus work and subsequent demonstrations) established that synthetic-genomics methods could in principle be used to construct dangerous pathogens. The biosecurity question remains an active area of policy concern, with debates about the regulation of commercial DNA synthesis, the screening of synthesis orders for hazardous sequences, and the broader oversight of dual-use research continuing across national and international institutions. - **The species-scale and ecosystem-scale aspirations.** The longer-term aspirations of synthetic genomics — the design of complete multicellular organisms, the design of complete ecosystems, the construction of biospheres adapted to specific environmental conditions — remain far beyond contemporary capability. Whether these aspirations are realisable on any timescale is a question the field's current trajectory does not yet permit assessment of. ## In the Wheel of Heaven framework The framework's interest in synthetic genomics is treated at full length in the [life engineering](../life-engineering/) entry, where the broader convergence argument between contemporary terrestrial life-engineering capability and the source material's account of the Elohim's work is developed. The treatment below addresses what is specific to synthetic genomics — the scale of operation, the constructive epistemology applied at the level of complete organisms, and the specific match between whole-genome synthesis and the source material's account of the Elohim's biological-design work — and the ways in which these features illuminate the framework's reading of the source material. ### The scale match The framework's reading attends specifically to the *scale* at which synthetic genomics operates: the level of complete genomes, complete cellular organisms, complete biological systems built from designed sequence. Where genetic engineering modifies existing genomes and synthetic biology designs sub-systems, synthetic genomics is the sub-discipline that operates at the scale of the whole organism. This is the scale at which the Raëlian source material describes the work of the Elohim. The source material describes the Elohim's biological-design work in operational terms that imply whole-organism design: the synthesis of complete plants, complete animals, complete humans from designed genetic sequence. The source does not describe the Elohim as modifying pre-existing terrestrial life; it describes them as constructing terrestrial life from the ground up, beginning with the design of the organisms' DNA and proceeding through the assembly and propagation of the resulting biological forms. The operational scale is whole-organism scale. Contemporary terrestrial synthetic genomics is the sub-discipline that operates at the same scale, at the lower bound. The JCVI minimal cells are whole organisms constructed from designed DNA; the Sc2.0 yeast is a whole eukaryotic organism whose genome has been systematically redesigned and synthesised; the broader synthetic-genomics programme is the discipline whose scale of operation most directly matches the scale at which the source material describes the Elohim's work. The framework reads this scale match as one of the structural features of the convergence between contemporary terrestrial capability and the source material's account. The convergence is not merely that humanity is doing some kind of biological engineering; the convergence is that humanity is doing biological engineering *at the scale* the source material attributes to the Elohim — beginning with single-cell organisms, with the trajectory pointing toward larger scales. ### The constructive epistemology at organism scale The constructive epistemology — that genuine understanding requires the ability to build — is shared between synthetic biology and synthetic genomics, but synthetic genomics applies it at the scale at which it most directly matches the source material's account. The Feynman motto encoded in the JCVI-syn1.0 watermarks ("What I cannot build, I cannot understand") expresses the same commitment the source material attributes to the Elohim's scientific programme: that the design and construction of complete organisms is both the validation of biological understanding and the production of working biological systems. The framework reads the convergence at the level of epistemology as significant. The source material did not describe the Elohim as having a mystical or supernatural understanding of biology; it described them as having a constructive understanding — the understanding that comes from being able to design and build the organisms one is studying. This is the epistemology that synthetic genomics has developed for contemporary terrestrial biology, at the scale at which the source material would describe it. ### The trajectory across scales The framework reads the *trajectory* of synthetic genomics across scales — from viral genomes (kilobase scale, 2002–2003) through bacterial genomes (megabase scale, 2008–2010) through minimal cells (reduced bacterial genomes, 2016–2021) through eukaryotic genomes (Sc2.0, 12 megabases) — as the developmental arc the source material's account predicts for any civilisation moving from pre-life-engineering to mature life-engineering capability. The Elohim, on the source material's account, traversed this developmental arc themselves, beginning with the laboratory production of primitive cellular forms and developing across an extended period into the species- and ecosystem-scale capability that produced the Earth project. The trajectory contemporary terrestrial synthetic genomics is currently traversing — from bacterial genomes through eukaryotic genomes toward eventual multicellular and ecosystem-scale synthesis — is the trajectory the source material would describe as the Elohim's own developmental path. The framework treats the trajectory's direction and scale-progression as significant. The current scale of synthetic genomics (single-cell organisms) does not match the Elohim's scale (multicellular organisms, including humans). What does match is the trajectory: contemporary terrestrial capability is moving toward the scale the source material attributes to the Elohim, and the rate of progress across scales has been substantial across the past two decades. ### The minimal cell and the source material's account of cellular origins A specific connection bears registering. The Raëlian source material describes the Elohim's early laboratory work, prior to the Earth project, as the production of primitive cellular forms in laboratory conditions — the synthesis of the simplest viable cellular life from designed components. The JCVI-syn3.0 minimal cell is, in contemporary terrestrial terminology, this exact thing: a primitive minimal cellular form synthesised in laboratory conditions with the smallest genome consistent with viable cellular life. The match between the source material's description of the Elohim's early state and the contemporary state of terrestrial synthetic genomics at its leading edge is one of the specific evidential features the framework's reading attends to. The source material's broader trajectory — from minimal cellular forms through more complex organisms toward the species- and ecosystem-scale capability — is the trajectory contemporary synthetic genomics would have to traverse to reach the Elohim's scale. Whether terrestrial life engineering will in fact traverse this trajectory, on what timescale, and with what consequences, is the open question the framework treats as the most important near-term empirical test of the source material's broader claims. ### Astrobiology and the pan-tropic question The source material describes the Elohim as having undertaken the Earth project after arrival on a planet whose conditions required the design of organisms specifically adapted to terrestrial environmental conditions — the work proceeded by surveying the planet, characterising its conditions, and designing organisms suited to the conditions found. This is the *pan-tropic* problem in astrobiological terminology: the design of organisms adapted to specific planetary environments rather than for the universal-purpose conditions of any given home laboratory. Synthetic genomics is the discipline best positioned to address the pan-tropic problem in contemporary terrestrial science. The construction of organisms designed for survival under non-terrestrial conditions — extreme temperature, high radiation, non-standard atmospheric composition, low water availability — requires the design of complete genomes incorporating the relevant protective and metabolic features. Several research programmes are pursuing relevant aspects, although the capability does not yet exist at the level required for designing organisms adapted to genuinely non-terrestrial conditions. The framework reads the contemporary emergence of pan-tropic synthetic genomics as the further structural feature the source material would predict. The Elohim, on the source material's account, were a civilisation that had developed precisely the capability to design organisms for specific planetary environments — the capability synthetic genomics is in the early phase of developing. The eventual extension of synthetic-genomics methods to the design of organisms suited to off-Earth environments — for laboratory study of how such organisms would behave, or eventually for off-Earth deployment — would be the further development of the same capability the source material attributes to the Elohim civilisation. ### The position within the broader framework reading The synthetic-genomics entry's contribution to the broader framework is the specific observation that the *scale* at which contemporary synthetic genomics operates is the scale at which the source material describes the Elohim's work. The synthetic-biology entry's contribution is the observation that the *methodology* of synthetic biology matches the source material's operational vocabulary. The two together — scale match and methodology match — are the framework's two principal evidential features for the life-engineering convergence as a whole. The broader convergence argument is developed in the [life engineering](../life-engineering/) entry; the framework reading of the wider corpus is developed across the dedicated entries on the [Age of Aquarius](../timeline/age-of-aquarius/), the [Cosmic Chain](../cosmic-chain/), and the broader chapter material. ## Comparative observations The corpus's reading of synthetic genomics sits within a broader landscape of how the field has been interpreted across different traditions of commentary. A brief survey clarifies the corpus's reading by contrast. ### The mainstream scientific reading The mainstream scientific reading of synthetic genomics treats the field as a contemporary engineering discipline with substantial scientific and biotechnological potential. The field is interpreted within the standard scientific worldview: living systems are products of evolution, the engineering of complete genomes is a contemporary human capability with practical implications, and the broader questions of meaning are not within the field's scope. The contemporary minimal cell, on the mainstream reading, is a remarkable scientific achievement and a useful research tool but not a development with metaphysical or theological implications. The corpus's reading does not contest the mainstream scientific reading at the level of empirical facts. What it contests is the interpretive frame within which those facts are placed. The corpus reads the contemporary emergence of synthetic genomics as the present-day local instance of a capability the source material attributes to a non-terrestrial civilisation in deep antiquity; the mainstream scientific reading treats the contemporary emergence as the autonomous achievement of contemporary human science. The two readings differ at the level of interpretive significance rather than at the level of empirical content. ### The bioethical and theological readings The bioethical and theological commentary on synthetic genomics has been substantially shaped by the JCVI minimal-cell work. The 2010 publication of JCVI-syn1.0 produced a substantial wave of bioethical and theological commentary, including statements from the Vatican (which characterised the work as a significant scientific achievement that did not, on the Vatican's reading, constitute the creation of life de novo because the synthetic genome was assembled from existing biological information), from various Protestant theological bodies (with positions ranging from cautious acceptance to substantive concern), and from various secular bioethical commentators (with similarly varied positions). The principal questions the bioethical and theological literature has engaged include: whether the synthetic minimal cell constitutes the *creation of life* in any genuinely new sense, whether the field's broader trajectory represents an appropriate or inappropriate human appropriation of capabilities historically associated with the divine, what the appropriate regulatory framework for the field should be, and what the broader societal implications of the field's continued development are. The corpus's reading is partially aligned with several of the bioethical and theological readings — both treat the contemporary emergence of synthetic genomics as developmentally significant — but differs in the specific account of why. The bioethical and theological readings typically work within the standard interpretive frames of their respective traditions (Catholic theology, Protestant theology, secular bioethics); the corpus's reading works within the framework of the Raëlian source material and treats the contemporary emergence as the present-day local instance of the source material's account of biological design. ### The transhumanist and futurist readings The transhumanist and futurist literature has interpreted synthetic genomics as one component of an emerging set of technologies — alongside artificial intelligence, advanced biotechnology, and others — that together represent the beginning of a developmental phase in which human capability extends substantially beyond current limits. The transhumanist reading shares with the corpus's reading the interpretation of synthetic genomics as more than a routine engineering discipline, but differs in the specific framework within which the development is placed. The transhumanist literature typically frames the development as the early phase of a post-human or trans-human transition; the corpus frames it as the early phase of humanity reaching the position the source material describes as the Elohim's own pre-Earth-project state. ### The Sendy–Raëlian tradition Within the specific Sendy–Raëlian interpretive tradition that the corpus reads as its principal scholarly antecedent, the framework's reading of synthetic genomics is consistent with Sendy's broader reading and develops it forward. Sendy, writing in 1968–1974, did not have the benefit of the subsequent fifty years of scientific development; his identification of the Elohim as biological engineers, working at the molecular level on the design and synthesis of complete organisms, was based on his philological-historiographic reading of the Hebrew Bible. The subsequent development of synthetic genomics vindicates Sendy's reading in the specific sense that the whole-organism design capability he attributed to the Elohim has now been partially demonstrated by terrestrial human science — at the single-cell level, with the trajectory pointing toward larger scales. The framework reads this as the kind of vindication a philological reconstruction is positioned to receive from independent empirical development. ## See also - [Life engineering](../life-engineering/) - [Synthetic biology](../synthetic-biology/) - [Genetic engineering](../genetic-engineering/) - [Xenobiology](../xenobiology/) - [Genesis](../genesis/) - [Elohim](../elohim/) - [Tree of Life](../tree-of-life/) - [Age of Aquarius](../timeline/age-of-aquarius/) - [Age of Capricorn](../timeline/age-of-capricorn/) - [Apocalypse](../apocalypse/) - [Cosmic Chain](../cosmic-chain/) - [Cosmic Competition](../cosmic-competition/) - [Jean Sendy](../jean-sendy/) - [Raël](../rael/) - [*Message from the Designers*](../library/message-from-the-designers/) ## References Vorilhon, Claude (Raël). *The Book Which Tells the Truth* (1974) and *Extraterrestrials Took Me to Their Planet* (1976), collected as *Message from the Designers* (Raëlian Foundation, current English edition). Sendy, Jean. *La Lune, clé de la Bible*. Julliard, 1968. Sendy, Jean. *Ces dieux qui firent le ciel et la terre*. Robert Laffont, 1969. English: *Those Gods Who Made Heaven and Earth*. Berkley, 1972. Ball, Philip. *How Life Works: A User's Guide to the New Biology*. Picador / University of Chicago Press, 2023. Smith, Hamilton O., Clyde A. Hutchison III, Cynthia Pfannkoch, and J. Craig Venter. "Generating a Synthetic Genome by Whole Genome Assembly: φX174 Bacteriophage from Synthetic Oligonucleotides." *Proceedings of the National Academy of Sciences* 100 (2003): 15440–15445. Cello, Jeronimo, Aniko V. Paul, and Eckard Wimmer. "Chemical Synthesis of Poliovirus cDNA: Generation of Infectious Virus in the Absence of Natural Template." *Science* 297 (2002): 1016–1018. Gibson, Daniel G., et al. "Complete Chemical Synthesis, Assembly, and Cloning of a *Mycoplasma genitalium* Genome." *Science* 319 (2008): 1215–1220. Gibson, Daniel G., et al. "Enzymatic Assembly of DNA Molecules Up to Several Hundred Kilobases." *Nature Methods* 6 (2009): 343–345. [Gibson assembly.] Gibson, Daniel G., et al. "Creation of a Bacterial Cell Controlled by a Chemically Synthesized Genome." *Science* 329 (2010): 52–56. [JCVI-syn1.0.] Hutchison, Clyde A., III, et al. "Design and Synthesis of a Minimal Bacterial Genome." *Science* 351 (2016): aad6253. [JCVI-syn3.0.] Pelletier, James F., et al. "Genetic Requirements for Cell Division in a Genomically Minimal Cell." *Cell* 184 (2021): 2430–2440. [JCVI-syn3A.] Annaluru, Narayana, et al. "Total Synthesis of a Functional Designer Eukaryotic Chromosome." *Science* 344 (2014): 55–58. [Sc2.0 first complete synthetic chromosome (synIII).] Richardson, Sarah M., et al. "Design of a Synthetic Yeast Genome." *Science* 355 (2017): 1040–1044. [Sc2.0 overall design overview.] Boeke, Jef D., et al. "The Genome Project-Write." *Science* 353 (2016): 126–127. [GP-write project proposal.] Lajoie, Marc J., et al. "Genomically Recoded Organisms Expand Biological Functions." *Science* 342 (2013): 357–360. [Church and Isaacs group, codon recoding.] Fredens, Julius, et al. "Total Synthesis of *Escherichia coli* with a Recoded Genome." *Nature* 569 (2019): 514–518. [The Syn61 / rE.coli work.] Venetz, Jonathan E., et al. "Chemical Synthesis Rewriting of a Bacterial Genome to Achieve Design Flexibility and Biological Functionality." *Proceedings of the National Academy of Sciences* 116 (2019): 8070–8079. [Caulobacter ethensis-2.0.] Hutchison, Clyde A., III, et al. "Polishing the Genome of a Minimal Cell." *Cell* 184 (2021): 2410–2417. J. Craig Venter Institute. "First Minimal Synthetic Bacterial Cell." J. Craig Venter Institute. "First Self-Replicating, Synthetic Bacterial Cell Constructed." Synthetic Yeast 2.0 (Sc2.0) Consortium. GP-write (Genome Project-write). National Academies of Sciences, Engineering, and Medicine. *Biodefense in the Age of Synthetic Biology*. National Academies Press, 2018. "Synthetic genomics." *Wikipedia*. "Mycoplasma laboratorium." *Wikipedia*. "Synthetic Yeast Project (Sc2.0)." *Wikipedia*. "Caulobacter ethensis-2.0." *Wikipedia*.